English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 848141      Online Users : 811
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10716


    Title: Palliative meflep therapy in advanced pancreatic cancer: Excellent response in a patient with her-2/neu amplification
    Authors: Chao, Y;Liu, JM;YauLi, AF;Perng, CL;Tiu, CM;King, KL;Chen, LT;Lin, WC;Lan, C;Whang-Peng, J
    Contributors: National Institute of Cancer Research
    Abstract: Introduction Patients with pancreatic cancer often present initially in advanced disease with many compromising factors, and yet they may still be responsive to chemotherapy. Aims The response of 23 patients with advanced pancreatic cancer to continuous infusion therapy was investigated. Methodology From September 1995 to February 1998, 23 patients with advanced pancreatic cancer, many with compromising factors, were treated with a MEFLEP regimen: biweekly 24-hour infusions of etoposide, 5-fluorouracil, leucovorin, epirubicin, and cisplatin, all given through an infusion pump, plus megestrol acetate, 160 mg/d, taken daily. A total of 145 courses were given. Overall response rate was 21% (4/19) for assessable chemo-naive patients; median survival for all 23 patients was 6 months; 22% of patients were alive at 1 year; and a clinical response benefit was attained in 35%. Results Toxicity was manageable; grade 3 or 4 leukopenia occurred in 1 patient each, 1 patient had fever and grade 3 infection, and grade 3 and 4 hyperammonemic encephalopathy developed in 3 and 1 patients, respectively. All four of the latter patients recovered uneventfully within 2 days of initiation of therapy. Nine patients were evaluated by fluorescence in situ hybridization for the Her-2/ neu oncogene, but for only one patient did amplification of the gene occur. She attained complete remission with treatment and lived for 26.7 months after diagnosis. Conclusion Biweekly MEFLEP is an active and manageable regimen for patients with advanced pancreatic cancer with compromised clinical status.
    Date: 2002-07
    Relation: Nursing. 2002 Jul;25(1):e10-e14.
    Link to: https://insights.ovid.com/pubmed?pmid=12131783
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=18744393407
    Appears in Collections:[彭汪嘉康(1996-2007)] 期刊論文
    [陳立宗] 期刊論文
    [劉敏(1996-2007)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    SCP18744393407.pdf555KbAdobe PDF381View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback